Clinical Trial

A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis

Study acronym: ADtouch
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with atopic hand and foot dermatitis. This study lasts up to 32 weeks, including a 6-week screening period, a 16-week treatment period, and a safety follow-up visit 12 weeks after the last dose.
Protocol Amendment History 3 changes
notable Trial sites reduced: 79 -> 76 locations 2026-06-26
notable Primary completion moved earlier: 2026-07 -> 2026-05 2026-04-18
minor Completion moved earlier: 2026-09 -> 2026-07 2026-04-18
Trial Details
NCT Number NCT06921759
Lead Sponsor Eli Lilly and Company
Conditions Atopic Hand and Foot Dermatitis
Enrollment 221 participants
Start Date 2025-04-21
Primary Completion 2026-05-13 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-25